ストックスクリーナーアプリを入手
6.72
2.44%
0.16
アフターアワーズ：
6.72
Cybin Inc (CYBN) 最新ニュース
Cboe Canada Single Security - Cboe Global Markets
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin secures new patent for depression treatment drug - Investing.com
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace
Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus
Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com
Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin to Participate at the 28th Annual Milken Institute Global Conference - The Joplin Globe
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI - The Globe and Mail
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
(CYBN) Trading Report - news.stocktradersdaily.com
Cybin (CYBN) Partners with Osmind for Psychedelic Therapy Launch - GuruFocus
Psychedelic drug developer Cybin partners with Osmind (CYBN:NYSE) - Seeking Alpha
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - 01net
Cybin Partners With Osmind to Support Psychiatry Program Pipeline - marketscreener.com
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs | CYBN Stock News - GuruFocus
Cybin's Game-Changing Mental Health Partnership: 800+ Clinics to Deploy Novel Depression and Anxiety Treatments - Stock Titan
Where are the Opportunities in (CYBN) - news.stocktradersdaily.com
Filament Health secures investment to remedy concerning financial position - Mugglehead Magazine
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):